Parabilis Medicines, Inc. (PBLS) vs Regencell Bioscience Holdings Limited (RGC)
A side-by-side comparison of Parabilis Medicines, Inc. and Regencell Bioscience Holdings Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PBLS
Parabilis Medicines, Inc.
$28.57HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
RGC
Regencell Bioscience Holdings Limited
$7.65HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
Total return — PBLS vs RGC
growth of $100 · dividends reinvested · last 1yPBLS +47.7% (+47.7%/yr)RGC -66.2% (-66.2%/yr)PBLS compounded faster over this window
PBLS RGC
PBLS vs RGC: by the numbers
- •RGC is the larger company ($3.79B vs $3.33B market cap).
Metrics side by side
Valuation
| Metric | PBLS | RGC |
|---|---|---|
| P/B ratio | 3.18 | 3108.44 |
Profitability
| Metric | PBLS | RGC |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | N/A | -73.75% |
| ROIC | -409.85% | -69.75% |
Growth (annualized)
| Metric | PBLS | RGC |
|---|---|---|
| Total return CAGR (5Y) | N/A | 67.94% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.